CSIMarket
 
Societal Cdmo Inc   (NASDAQ: SCTL)
Other Ticker:  
 
 
Price: $1.0900 $0.00 0.000%
Day's High: $1.1 Week Perf: 0.93 %
Day's Low: $ 1.09 30 Day Perf: 2.83 %
Volume (M): 810 52 Wk High: $ 1.10
Volume (M$): $ 883 52 Wk Avg: $0.89
Open: $1.09 52 Wk Low: $0.44



 Market Capitalization (Millions $) 103
 Shares Outstanding (Millions) 95
 Employees 300
 Revenues (TTM) (Millions $) 95
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 8

Societal Cdmo Inc
Societal CDMO Inc is a bi-coastal contract development and manufacturing organization, providing end-to-end regulatory support, clinical and commercial manufacturing, packaging, and logistics services to the global pharmaceutical market. They specialize in small molecules, handling DEA-controlled substances, and developing and manufacturing modified-release dosage forms. They have three state-of-the-art facilities, totaling 145,000 square feet, in Gainesville, Georgia and San Diego, California. They have expertise in solving complex manufacturing problems and are a leading CDMO in the industry. They also manufacture key products, including Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR, and Donnatal liquids and tablets. Societal CDMO's mission is to improve patient lives through client partnerships, and their vision is to be a premier, trusted CDMO by bringing tailored solutions to their clients while fostering engaging and rewarding careers for their people. Their strategy for growth includes executing segment-specific sales and marketing strategies, building stronger visibility and identity for the organization, enhancing both customerse and employeese experiences, and continuing to achieve growth and strengthen their financial position.


   Company Address: 1 E. Uwchlan Ave, Suite 112 Exton 19341 PA
   Company Phone Number: 534-8239   Stock Exchange / Ticker: NASDAQ SCTL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CDMO        0.4% 
CORT        2.19% 
CTLT        0.38% 
TMO   -5.35%    
• View Complete Report
   



Merger and Acquisition

CoreRx, Inc. Expands Footprint in CDMO Sector with Acquisition of Societal CDMO, Inc.

Published Mon, Apr 8 2024 8:06 PM UTC

CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.
Clearwater, Fla., April 08, 2024 - CoreRx, Inc. (CoreRx), a leading contract development and manufacturing organization (CDMO), has recently finalized its acquisition of Societal CDMO, Inc. (Societal CDMO) (Nasdaq: SCTL). This strategic move aims to strengthen CoreRx s capabilities in solving complex formulation a...

Merger and Acquisition

Groundbreaking Acquisition of Societal CDMO by CoreRx Inc. Set to Revolutionize the CDMO Industry

Published Wed, Feb 28 2024 9:29 PM UTC



In a recent press release, Societal CDMO Inc. announced its definitive agreement to be acquired by CoreRx, Inc., a leading pharmaceutical Contract Development and Manufacturing Organization (CDMO). The partnership aims to establish a highly comprehensive CDMO with unparalleled capabilities encompassing early-stage formulation development through to commercial manuf...

Contract

Powerhouse Partnership: Societal CDMO and Benuvia Uphold Drug Development in Psychedelic and Cannabinoid Markets

Published Thu, Feb 1 2024 12:01 PM UTC

Societal CDMO and Benuvia Sign Co-Marketing Agreement to Boost Drug Development Services in Thriving Psychedelic and Cannabinoid MarketsTwo prominent players in the contract development and manufacturing organization (CDMO) and active pharmaceutical ingredient (API) manufacturing services, Societal CDMO and Benuvia, have recently joined forces through a co-marketing agreemen...

Societal Cdmo Inc

Societal Cdmo Inc Announces Phenomenal Revenue Growth in Q3 2023, Yet Faces Challenging Financial Struggles



Societal Cdmo Inc, a major player in the Pharmaceutical Preparations industry, recently released its financial results for the third quarter of 2023. The company experienced a significant rise in revenue, outperforming its industry peers. However, the revenue growth was not sufficient to reach breakeven, leading to an increased deficit per share. This article examines the financial results, compares them to previous periods, and provides insights into the company's performance within its industry.
Financial Results Overview:
In the third quarter of 2023, Societal Cdmo Inc reported a year-on-year revenue increase of 9.269%, amounting to $23.59 million. Although this surge is positive, it wasn't enough for the company to break even. As a result, they recorded a deficit per share of $-0.05, indicating financial challenges.

Societal Cdmo Inc

Societal Cdmo Inc Delivers Remarkable Turnaround, Boosts Financial Performance in Q2 2023

Societal Cdmo Inc, a prominent company in the CDMO (Contract Development and Manufacturing Organization) industry, has recently released its financial report for the April to June 30, 2023 period. Despite facing challenges in the market, the company has shown some improvements in its financial performance.
One notable development is the decrease in the loss per share from $-0.06 in the previous year to $-0.04 in the current financial period. This showcases the company's efforts to manage its expenses efficiently and minimize losses. Furthermore, the income per share also improved from the previous financial reporting period, indicating a positive trend for Societal Cdmo Inc.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com